Quarterly ResultAug 5, 2026, 02:33 PM
LivaNova Q2 Net Income $108.6M; FDA Approves aura6000 System
AI Summary
LivaNova reported strong financial results for the second quarter and first half of 2026, with net income significantly increasing compared to the prior year, largely due to the absence of a substantial environmental liability expense. The company also achieved a key regulatory milestone by receiving FDA Premarket Approval for its aura6000 System in March 2026, which led to a $60.5 million contingent consideration payment. Additionally, LivaNova made a $95.9 million early repayment of its Term Facilities in January 2026.
Key Highlights
- Received FDA Premarket Approval (PMA) for the aura6000 System in March 2026.
- Q2 2026 net revenue increased to $390.6 million from $352.5 million year-over-year.
- Q2 2026 net income rose to $108.6 million from $27.2 million year-over-year.
- Diluted EPS for Q2 2026 was $1.93, up from $0.50 year-over-year.
- H1 2026 net income was $130.9 million, a significant improvement from a $300.2 million loss.
- Repaid $95.9 million of Term Facilities in January 2026.
- Paid $60.5 million for ImThera contingent consideration in June 2026.
Price Impact
More from LIVN